Today: 18 December 2025
Subscribe
Browse Category

Healthcare Policy News 6 November 2025 - 18 December 2025

Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Analyst Price Targets, Medicare Pricing Pressure, and Pipeline Catalysts (Dec. 18, 2025)

Pfizer Stock (NYSE: PFE) News Today: 2026 Guidance, Analyst Price Targets, Medicare Pricing Pressure, and Pipeline Catalysts (Dec. 18, 2025)

Pfizer (NYSE: PFE) stock is trying to regain its footing on Thursday, December 18, 2025, after a volatile mid-December stretch that put the spotlight back on three recurring themes for shareholders: the post-COVID revenue reset, looming loss-of-exclusivity (LOE) headwinds, and
18 December 2025
 ·  ·  ·  · 
UK–Singapore Regulatory Innovation Corridor Launched: MHRA, HSA and Flagship Pioneering Aim to Speed Breakthrough Health Technologies

UK–Singapore Regulatory Innovation Corridor Launched: MHRA, HSA and Flagship Pioneering Aim to Speed Breakthrough Health Technologies

London/Singapore — December 13, 2025 — UK and Singapore health regulators have unveiled a new cross-border “Regulatory Innovation Corridor” designed to help developers move breakthrough medicines, medical technologies and advanced diagnostics to patients faster—without lowering safety standards. The initiative, announced
13 December 2025
 ·  ·  ·  · 
AbbVie (ABBV) Stock Today, November 26, 2025: Share Price Dip Amid FDA Win, Medicare Drug Price Cuts and Bullish Options Signals

AbbVie (ABBV) Stock Today, November 26, 2025: Share Price Dip Amid FDA Win, Medicare Drug Price Cuts and Bullish Options Signals

AbbVie Inc. (NYSE: ABBV) is trading lower today, but the big pharma giant remains near multi-year highs as investors digest a powerful mix of good news (a major FDA approval, strong Q3 numbers) and growing policy headwinds from U.S. Medicare
26 November 2025
 ·  ·  ·  ·  · 
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 7, 2025): NVO Slips as U.S. Wegovy/Ozempic Price Cuts Take Center Stage; Medicare Coverage, FTC Scrutiny and Metsera Bid in Focus

Summary: Novo Nordisk’s U.S.-listed shares (NYSE: NVO) traded lower on Friday after the company and Eli Lilly agreed to cut U.S. prices on GLP‑1 medicines to expand access, including under Medicare. The deal introduces near‑term revenue pressure but could lift
7 November 2025
 ·  ·  ·  ·  · 
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

NVO Stock Today (Nov 6, 2025): Novo Nordisk volatile as White House pricing deal reshapes GLP‑1 market—what it means for Wegovy, Ozempic and investors

Published: November 6, 2025 TL;DR: Novo Nordisk’s U.S.‑listed shares (NYSE: NVO) swung after the White House announced a pricing-and-access deal with Novo and Eli Lilly that expands Medicare coverage for anti‑obesity drugs and cuts out‑of‑pocket costs. As of 17:51 UTC
6 November 2025
 ·  ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (Nov 6, 2025): NVO steadies as White House GLP‑1 pricing deal lands; $10B Metsera bidding war heats up

Date: Thursday, November 6, 2025Ticker: NVO (NYSE) At a glance: price action and catalysts Novo Nordisk stock traded around $47.36 as of 17:52 UTC, after opening at $47.75 and moving between $46.91–$49.49 on heavy volume. The tape is being driven
6 November 2025
 ·  ·  ·  ·  · 
Go toTop